These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25140867)

  • 1. The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.
    Camuglia AC; Waddell-Smith KE; Hammett CJ; Aylward PE
    Curr Med Res Opin; 2014 Nov; 30(11):2151-67. PubMed ID: 25140867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.
    Shivu GN; Ossei-Gerning N
    Vasc Health Risk Manag; 2014; 10():291-302. PubMed ID: 24868164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review.
    Khalil P; Kabbach G
    Curr Cardiol Rep; 2019 Jan; 21(1):5. PubMed ID: 30689068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antithrombotics for secondary prevention of acute coronary syndrome.
    Goto S; Tomita A
    Clin Cardiol; 2014 Mar; 37(3):178-87. PubMed ID: 24452610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anticoagulant therapy in secondary prevention of coronary events].
    Bultas J
    Vnitr Lek; 2014 Dec; 60(12):1023-32. PubMed ID: 25692828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of rivaroxaban in patients with acute coronary syndrome.
    Fitchett DH
    Drug Des Devel Ther; 2012; 6():349-57. PubMed ID: 23209364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants in acute coronary syndrome.
    Ahrens I; Bode C
    Semin Hematol; 2014 Apr; 51(2):147-51. PubMed ID: 24861799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivaroxaban for the treatment of acute coronary syndromes.
    Wong CK; White HD
    Expert Opin Pharmacother; 2013 May; 14(7):917-27. PubMed ID: 23544968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.
    Cohen M; Iyer D
    Cardiovasc Ther; 2014 Oct; 32(5):224-32. PubMed ID: 24894120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
    Weitz JI
    Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban (Xarelto) for acute coronary syndrome.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):97. PubMed ID: 22173426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants in acute coronary syndrome.
    Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
    Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation and antiplatelet therapy in acute coronary syndromes.
    Singh D; Gupta K; Vacek JL
    Cleve Clin J Med; 2014 Feb; 81(2):103-14. PubMed ID: 24493493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?
    Deftereos S; Bouras G; Giannopoulos G; Kossyvakis C; Panagopoulou V; Pyrgakis V; Stefanadis C
    Curr Clin Pharmacol; 2012 Aug; 7(3):195-208. PubMed ID: 22564121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.